KLTO ANEW Medical: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The business model of Klotho Neurosciences Inc (KLTO) relies on the study of the Klotho protein to slow neuronal aging and the protection of unique therapeutic methodologies. This chart illustrating share price dynamics through the lens of EV/EBITDA is 0.00. However, the company faces intense pressure from industry behemoths in the race for leadership in dementia treatment, while a lack of profitability necessitates a reliance on external investments and strict cash management.

This indicator compares the total enterprise value to its operating profit before depreciation and amortization, determining the market premium for cash flow generation regardless of debt load. By analyzing the EV/EBITDA multiple chart, an investor assesses the efficiency of capital expenditures by Klotho Neurosciences Inc (KLTO) in developing neurobiological therapies against aging and Parkinson's disease for expansion into the geriatric drug market.